Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2020-12-17 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release dated December 17, 2020, announcing positive first results from a clinical trial regarding the safety of continuous administration of Ivermectin for Covid-19 prophylaxis, developed by MedinCell. It details preliminary study results, participant cohorts, regulatory authorization (MHRA), and future formulation development plans. This content structure—a formal announcement of scientific/clinical progress and business updates outside of standard periodic financial reports (10-K, IR, ER)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it focuses on clinical trial results and development milestones rather than just quarterly financial figures, it is best classified as an Earnings Release (ER) as it serves as the primary communication of recent operational performance/updates to the market, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the detailed nature of the results presentation, ER is a strong fit, as these often include operational highlights. However, since it is a scientific/clinical update rather than a standard quarterly financial summary, and it is a general announcement, it fits well under the broad category of an Earnings Release (ER) which covers key operational highlights, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure not covered elsewhere. Given the context of presenting 'first results' and development progress, ER is the most appropriate fit among the specific options, as it communicates key performance indicators (clinical safety data) to investors. FY 2020
2020-12-17 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 17, 2020, announcing positive preliminary results from a Phase 1 clinical study regarding the safety and pharmacokinetics of Ivermectin administration, specifically in the context of developing a long-acting injectable formulation (mdc-TTG) for Covid-19 prevention. It details study design, preliminary safety findings, and future regulatory plans. This type of announcement, focusing on clinical trial updates and pipeline progress, is characteristic of an Investor Presentation (IP) or a general press release about R&D progress. Since it is a detailed update on clinical trials and product development strategy, 'Investor Presentation' (IP) is the most fitting category, as these often contain detailed scientific/clinical updates intended for investors, even if formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it a short announcement of a report (RPA/RNS).
2020-12-17 French
Terms of availability of the preparatory documents for the GM
Regulatory Filings Classification · 99% confidence The document explicitly mentions an 'Ordinary Shareholders' Meeting' scheduled for December 15, 2020, and provides details about a 'Live webcast of the event'. It also mentions a specific resolution ('approve the appointment of Elisabeth Kogan to the Supervisory Board'). This content directly relates to materials and announcements concerning the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (2132 chars), but the content is substantive regarding the meeting itself, not just announcing a separate report, making AGM-R a better fit than RPA or RNS.
2020-12-11 English
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document title explicitly mentions "Retransmission en direct de l'Assemblée Générale du mardi 15 décembre 2020" (Live broadcast of the General Meeting of Tuesday, December 15, 2020). It discusses the General Meeting (AG), shareholder votes, and provides details on how to access the live stream. This content directly relates to the Annual General Meeting (AGM). Although it is an announcement about the broadcast, the core subject matter is the AGM itself, making AGM-R the most appropriate classification over a general RPA or RNS, as AGM-R is a specific category for AGM materials/information.
2020-12-11 French
Inside Information / News release on accounts, results
Earnings Release Classification · 95% confidence The document is a financial results announcement for MedinCell covering the first half of the 2020/2021 fiscal year (April-September 2020). It provides a summary of financial highlights, operational developments, and portfolio updates. While it contains financial data, it is structured as an earnings release (key highlights) rather than a full, comprehensive interim financial report. It follows the standard format of an Earnings Release (ER) by summarizing performance and key events for the period. H1 2021
2020-12-09 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 99% confidence The document is titled "MedinCell publie ses résultats financiers du premier semestre 2020-2021 (avril - septembre 2020)" and contains detailed financial figures (cash, assets) and extensive operational updates covering product pipelines, clinical trial progress, and management changes for the six-month period ending September 30, 2020. This structure—a comprehensive review of a specific interim period's financial and operational performance—is characteristic of an Interim/Quarterly Report (IR). It is too detailed to be a mere Earnings Release (ER) and is not the full annual filing (10-K). Since it covers a period shorter than a year (six months), the correct classification is IR. H1 2021
2020-12-09 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.